NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Afatinib for treating epidermal growth factor receptor mutation positive locally advanced or metastatic non-small cell lung cancer

Please sign and return to:

Donna Barnes, Technology Appraisal Administrator
Email: TACommD@nice.org.uk
Fax: +44 (0)20 7061 9752
Post: NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT

I confirm that:

- I agree with the content of the statement submitted by **Roy Castle Lung Cancer Foundation** and consequently I will not be submitting a personal statement.

Name: Jesme Fox

Sig

Date: 16.10.14